X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells. The company's oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in promoting the immunosuppressive and pro-angiogenic microenvironment of many cancers. X4P-001, the company's lead program, is expected to enter Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications, and its second program, X4P-002, is in pre-clinical development for oncology applications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/14/15 | $37,500,000 | Series A |
Cormorant Asset Management Maxim Group | undisclosed |
| 11/16/17 | $27,000,000 | Series B |
